Blocking the kynurenine pathway, a regulator of brain metabolism, can restore cognitive function in lab mice with Alzheimer’s disease. The pathway is overactivated in Alzheimer’s, disrupting glucose metabolism and starving neurons of energy. By inhibiting this pathway, researchers improved memory and brain plasticity in mice, offering hope for new treatments in humans. IDO1 inhibitors, currently in cancer trials, could be repurposed for Alzheimer’s treatment.

Research has revealed that individuals with multiple sclerosis (MS) are significantly less likely to exhibit the molecular signs of Alzheimer’s disease, suggesting a protective element in MS that could inspire new Alzheimer's treatments. The study found that MS patients had 50% less amyloid plaque accumulation, a key indicator of Alzheimer’s, compared to non-MS individuals. This connection between MS and reduced Alzheimer's risk highlights potential immune-related mechanisms that may be leveraged for therapeutic strategies.

A new study suggests that the risk of developing dementia in Parkinson’s disease patients may be lower or occur later than previously reported. Researchers analyzed data from two large studies, finding a 9% risk of dementia within 10 years for newly diagnosed patients and a 27% risk for those diagnosed for an average of six years. Factors increasing dementia risk included older age at diagnosis, being male, and lower education levels.

A new report highlights that addressing 14 modifiable risk factors from childhood could prevent or delay nearly half of dementia cases. The study identifies high LDL cholesterol and untreated vision loss as new significant risks. Implementing early interventions can improve cognitive health and reduce the burden of dementia globally. Researchers emphasize the importance of targeted policies and lifestyle changes to mitigate these risks.

A recent study suggests that a GLP-1 drug, liraglutide, may protect the brains of people with mild Alzheimer’s disease, slowing cognitive decline by 18% over one year. This effect is likely due to the drug’s ability to reduce brain inflammation, improve insulin resistance, and lower the impact of Alzheimer’s biomarkers.

A new study reveals that chronic and new anxiety are linked to a higher risk of dementia, while resolved anxiety shows no such association. Following 2,132 Australian individuals for 10 years, researchers found that chronic and new anxiety increased dementia risk by 2.8 and 3.2 times, respectively. Those whose anxiety began before age 70 faced even greater risks. The findings suggest that addressing anxiety could help prevent dementia.

Exercising our brains with daily habits like naps and memory workouts, instead of relying on smartphones, can reduce the risk of age-related dementia. A new study highlights the superiority of human intelligence over AI. The study emphasizes nurturing our brain's potential for healthy aging. It also offers practical tips for boosting brain power and maintaining real intelligence.

Researchers established new criteria for Limbic-predominant Amnestic Neurodegenerative Syndrome (LANS), a memory-loss condition often mistaken for Alzheimer's disease. Unlike Alzheimer’s, LANS progresses more slowly and has a better prognosis. The criteria help doctors diagnose LANS in living patients using brain scans and biomarkers. This advancement aids in better management and tailored treatments for memory loss.